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Available online 1 September 2015AbstractOsteoporosis is characterized by low bone mass, deteriorated bone architecture and increased risk of is fractures. The current available
treatments of osteoporosis comprise antiresorptive and anabolic treatments. Bisphosphonates and RANKL antibody are the most widely used
antiresorptive treatments while teriparatide is the only available anabolic treatment of osteoporosis. A common feature of antiresorptive as well
as anabolic treatment is that bone resorption and formation remain coupled. Both types of treatment therefore establish a period of positive
balance but because of the coupling, this period is temporary.
The focus of this review is two new classes of anti-osteoporosis treatments; inhibition of cathepsin K and inhibition of sclerostin. Through
very different mechanisms of action both may prove capable of uncoupling resorption and formation. Cathepsin K is a lysosomal cysteine
protease that degrades bone matrix proteins including collagen type I. Animal and human studies have demonstrated that inhibition of cathepsin
K leads to increased bone mass across species and reduced fracture risk in postmenopausal women.
Sclerostin activates the Wnt canonical pathway and stimulates bone formation through stimulation of osteoblast differentiation, proliferation
and survival. Short-term studies of antibody mediated inhibition of sclerostin in animals and postmenopausal women have consistently shown
stimulation of bone formation and reduced or unaltered bone resorption. Clinical studies in postmenopausal women have shown increases in
bone mass.
If these two new treatments demonstrate anti-fracture efficacy at the same level or better as the best of the currently approved treatments, they
will become valuable tools for improving the treatment of osteoporosis.
© 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction osteoporosis based on a bone mineral density (BMD) T-scoreOsteoporosis is characterized by low bone mass and dete-
riorated bone architecture [1,2]. Osteoporosis is common,
affecting one in three postmenopausal women and one in five
men, corresponding to 200 million women and men, world-
wide [3]. The immediate clinical consequence of osteoporosis
is fracture [4,5]. Furthermore, osteoporotic fractures, vertebral
as well as hip are associated with morbidity and increased
mortality [6e8].
Care of patients with osteoporosis has improved signifi-
cantly over the last 2e3 decades. The WHO definition ofE-mail address: bente.langdahl@aarhus.rm.dk.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).<2.5 made it possible to identify individuals at risk of
fracture before the first fracture [2]. FRAX™ and other similar
tools available for estimating future risk of fractures have
made it possible to further direct treatment to the patients at
the highest risk of fracture [9,10]. Several pharmacological
treatments have been developed and approved for clinical use.
Although this in principle should have lead to a personalized
approach to treatment, the choice of treatment is in many
countries restricted to the cheapest treatment. Other treatments
are only reimbursed if the first treatment has failed.
Optimal management of osteoporosis is also confronted
with other challenges. Patients with fractures due to osteopo-
rosis are treated by orthopedic surgeons who are primarily
focused on fracture treatment and not on the prevention of the
next fracture. Patients with fractures are therefore notElsevier B.V. This is an open access article under the CC BY-NC-ND license
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intervention that may prevent the next fracture. The gap in the
management of osteoporosis has been recognized and it has
been demonstrated that the most efficient way to overcome
this gap is by organizing a “fracture liaison service” where
dedicated personnel are responsible for guiding the patient
from the orthopedic department, through DXA and other in-
vestigations back to the general practitioner who in the end is
responsible for treatment and follow-up [11,12].
Other challenges comprise patients who do not respond to
existing treatments and patients or physicians stopping treat-
ment prematurely due to fear of long-term adverse effects of
existing therapies.
The current available treatments of osteoporosis comprise
antiresorptive and anabolic treatments. The antiresorptive
treatments are bisphosphonates, receptor activator of nuclear
factor kappa-B ligand (RANKL) antibody, and selective es-
trogen receptor modulators (SERM) [13]. They have different
mechanisms of action, but in the end they all inhibit osteoclast
function. Bisphosphonates and RANKL antibody are the most
widely used antiresorptive treatments. They are both generally
well tolerated, but osteonecrosis of the jaw and atypical femur
fractures are very rare side effects that have gained much
attention and are causing much concern [14,15].
Teriparatide (PTH1-34) is currently the only available
anabolic treatment of osteoporosis. Patients generally respond
well to teriparatide with impressive increases in bone mass
[16]. However, some patients are still left with a very low bone
mass after teriparatide treatment and in some of these patients
fractures cannot in a longer perspective be prevented by the
available antiresorptive treatments. It would therefore be
desirable to have the option of a second period of anabolic
treatment. This is currently not possible with teriparatide.
Bone modeling is the process by which bone grow and
adapt its shape accordingly during childhood, adolescence and
young adulthood. Bone remodeling is the process by which
old bone is replaced by new bone. The remodeling process is
characterized by five phases: Activation, resorption, reversal,
formation and resting, which are coupled in location and time.
Bone loss and osteoporosis are caused by a negative balance
between the amount of resorbed and subsequently formed
bone [17]. A common feature for the available treatments,
antiresorptive as well as anabolic is that bone resorption and
bone formation remain coupled. Existing antiresorptive
treatments suppress bone resorption and second to this bone
formation is also suppressed. The anabolic treatment avail-
able; teriparatide stimulates bone formation and as a conse-
quence of this bone resorption is also stimulated. Both types
of treatment therefore establish a period of positive balance
between bone formation and bone resorption, but because of
the coupling, this period is only temporary. It has been
speculated that this could be the explanation for the relatively
limited effect of existing treatments on the prevention of non-
vertebral fractures [18]. The mechanisms underlying fragility
at cortical and cancellous bone compartments are different. In
cancellous bone, fragility is associated with remodeling ac-
tivity, as a resorption cavity with its temporary thinning of thetrabeculae has been demonstrated to be a stress-riser with
increased risk of collapse of the trabeculae and subsequent
loss of trabecular connectivity. Due to the negative remodel-
ing balance in postmenopausal women and elderly men,
remodeling itself and especially increased remodeling activity
convey a risk of loss of trabeculae due to thinning of the
trabeculae and therefore the risk of a resorption lacunae
penetrating the trabeculae or due to two resorption lacunae on
each side of a trabeculae merging. The fragile situation in
cancellous bone can relatively quickly be restored by anti-
sorptives, because bone remodeling is significantly reduced
[19] and by teriparatide, because trabeculae are becoming
thicker [20]. The situation in cortical bone is different.
Fragility of cortical bone is associated with thinning of the
cortex and increased porosity. Both are caused by increased
remodeling activity. Bisphosphonates have demonstrated
limited ability to improve hip BMD and it has been suggested
that this is due to limited access to cortical bone [21].
Denosumab has been demonstrated to be potentially more
active at the cortical department, perhaps due to better access
[22]. Denosumab has been demonstrated to reduce cortical
porosity and continuously increase hip BMD over many years
[23], still the prevention of non-vertebral fractures is not
optimal. Teriparatide is able to stimulate endocortical bone
formation, but subsequently stimulates cortical remodeling,
leading to increased porosity and decreasing cortical volu-
metric BMD [24,25]. Because of these build in limitations of
the available treatments of osteoporosis, there is a need for
treatments that are capable of uncoupling bone resorption and
formation. Attempts have been made of combining existing
antiresorptives with teriparatide and additive effects have been
shown on BMD despite very different patterns of changes in
biochemical markers of bone turnover [26,27]. None of these
studies investigated if these regiments improved fracture
prevention.
The focus of this review will be two new classes of anti-
osteoporosis treatments; inhibition of cathepsin K and inhi-
bition of sclerostin. Both may prove to be able to uncouple
resorption and formation, although through very different
mechanisms of action.
2. Inhibition of cathepsin K2.1. Cathepsin KResorbing osteoclasts adhere very tightly to the bone sur-
face and seal off the resorption lacunae. The osteoclasts
generate an acidic environment in the lacunae by secreting
protons. Bone mineral is dissolved by the acidic environment
and the collagen and other non-collagenous proteins are
degraded by proteases. Cathepsin K is one of these proteases,
others include metalloproteinases. Cathepsin K is a lysosomal
cysteine protease that degrades bone matrix proteins including
collagen type I [28]. Cathepsin K is predominantly, but not
exclusively expressed in osteoclasts and is stored in lysosomes
until it is released into the resorption cavity, where it is acti-
vated by the acidic environment.
6 B.L. Langdahl / Osteoporosis and Sarcopenia 1 (2015) 4e21Cathepsin K transcripts have been detected in embryonic
lung epithelium, skin fibroblasts, macrophages and white ad-
ipocytes [29e32]. Furthermore, osteocytes have been found to
produce and release cathepsin K during lactation. It has been
suggested that osteocytic cathepsin K may be involved in
osteocytic osteolysis [33,34]. However, if the expression of
cathepsin K by osteocytes is relevant to human physiology
remains to be shown. It also remains to be investigated if
cathepsin K which usually requires an acidic environment for
activation is functional in the non-acidic environment of the
osteocyte or if osteocytic cathepsin K may have non-
proteolytic activities, for example, signaling.
Pycnodysostosis is an autosomal recessive disorder caused
by mutations in the cathepsin K gene (CTSK). Pycnodysos-
tosis is characterized by osteopetrosis, bone fragility, skull
deformities and acro-osteolysis of the distal phalanges [35].
Histological examinations of bone biopsies from patients with
pycnodysostosis have demonstrated that the number of oste-
oclasts was not increased; however, the osteoclasts did not
seem to be able to degrade matrix proteins properly, as the
osteoclasts had cytoplasmic vacuoles containing undigested
collagen fibrils [36]. Indices of bone formation were reduced
and examination of the trabecular structure revealed highly
disorganized lamellae with poor alignment of mineral crystals,
suggestive of poor bone quality [37]. The phenotype of pyc-
nodysostosis may suggest that lack of cathepsin K may have
unfavorable effects on bone quality despite favorable effects
on bone mass. If this is only caused by the lifelong absence of
cathepsin K is one of the key questions that have to be
answered before pharmacological inhibition of cathepsin K
can be considered for the treatment of osteoporosis.2.2. Preclinical studies of the effects of cathepsin KAnimal models of too much and no expression of cathepsin
K has been generated. Mice that over express cathepsin K have
increased bone turnover and reduced bone volume [38,39].
Mice that do not express cathepsin K because the gene has
been knocked out, have high bone mass of the vertebrae and
the long bones and increased cortical thickness; a bone
phenotype similar to the patients with pycnodysostosis [40]
Unlike the patients with pycnodysostosis, the cathepsin K
knock-out (CatK/) mice have normal bone length and skull
development. This may suggest that mice, unlike human be-
ings have other proteases that can degrade collagen during
skeletal development. Another difference between patients
with pycnodysostosis and the CatK/ mice is that while the
patients have normal osteoclast numbers and reduced numbers
of osteoblasts, the mice have increased numbers of both os-
teoclasts and osteoblasts [41].2.3. Cathepsin K inhibitors in clinical development
2.3.1. Odanacatib
Odanacatib is a selective inhibitor of cathepsin K. Odana-
catib is a reversible blocker of the cysteine moiety of the active
site. In enzyme inhibition assays, the selectivity of odanacatibtowards cathepsin K is 300 times higher than towards
cathepsin S and more than 1000 times higher than towards
other human cathepsins, for example cathepsins B and L [42].
Odanacatib is non-basic and hydrophobic and therefore dif-
fuses freely through cellular membranes and does not accu-
mulate in any organelle and therefore the relative selectivity of
odanacatib is maintained [43]. This is in contrary to for
example balicatib which accumulates in lysosomes and where
other cathepsins are found and therefore looses it specificity.
2.3.1.1. Preclinical investigations of odanacatib. The effects
of odanacatib were first investigated in a rabbit model. Six
months old skeletally mature female rabbits were ovariectom-
ised or sham operated and randomized to two doses of odana-
catib (4 or 9 mM/day), alendronate, or placebo for 27 weeks
[44]. Ovariectomy resulted in a significant bone loss at the
spine. Both doses of odanacatib and alendronate prevented this
bone loss completely. Although ovariectomy did not cause bone
loss at the proximal femur, treatment with the highest dose of
odanacatib and alendronate resulted in significant increases in
bone mass. Histomorphometric analyses of lumbar vertebrae
and central femur revealed that bone formation rate and
mineralization surface at trabecular, endocortical, and intra-
cortical surfaces were similar between odanacatib and placebo
treated rabbits, whereas these parameters were suppressed in
alendronate treated animals. Mechanical testing revealed
increased bone strength of the vertebrae. Furthermore, the
strong correlation seen between bone mass and bone strength
were maintained in odanacatib treated animals, suggesting that
bone material properties are intact [44].
The effects of odanacatib have also been investigated in a
non-humane primate model. Female rhesus monkeys, aged
13e23 years were ovariectomised or sham operated. The
ovariectomised monkeys were randomized to odanacatib 6 mg/
kg, odanacatib 30 mg/kg or placebo for 21 months [45]. The
odanacatib doses used resulted in plasma exposures of
approximately 0.3 and 0.6 times, respectively, the clinical
exposure seen in postmenopausal women treated with odana-
catib 50 mg weekly. Odanacatib 30 mg/kg suppressed bone
resorption markers by 55e90% throughout the study period and
suppressed bone formation markers by 35e70% compared to
placebo treated animals [45]. Plasma levels of tartrate resistant
acid phosphatase (TRAP)-5b, a marker of osteoclast number,
were similar in odanacatib and placebo treated animals,
whereas s-type 1 collagen cross-linked C-telopeptide (1CTP)
was increased, supporting the underlyingmechanism; cathepsin
K inhibition inhibits bone resorption without inhibiting osteo-
clasts. The two odanacatib doses increased BMD at the lumbar
spine and by 7% and 15%, respectively and BMD at the femoral
neck by 11% and 15%, respectively, compared to placebo
treated animals [45,46]. Mechanical testing demonstrated
increased bone strength at the femoral neck [46]. Quantitative
computed tomography (QCT) derived indices of bone strength
tended to increase in the odanacatib treated animals and as in the
rabbits the correlation between bone mass and bone strength
(QCT and mechanical testing) was preserved [45,46]. Histo-
morphometric analyses of vertebrae, proximal femur and
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number of osteoclasts (resorption depth was not assessed)
compared to placebo treated animals, but reduced bone for-
mation at trabecular surfaces [45,46]. The latter finding was in
contrast to the findings in the rabbit study mentioned above
[44]. At the cortex, treatment with odanacatib preserved or
enhanced endocortical bone formation and stimulated
modeling-based bone formation at the periosteal surfaces,
resulting in a 20% increase in cortical thickness at the proximal
femur [46].
Bone mineral density distribution can be evaluated by
quantitative backscattered electron imaging (QBEI). By
applying this method, it was demonstrated that odanacatib
treatment of ovariectomised monkeys leads to increased
mineralization of trabecular bone, consistent with reduced
remodeling, whereas the distribution of mineralization was
unchanged at cortical bone sites, consistent with maintained
endocortical remodeling and stimulated periosteal bone
modeling [47].
Another study in ovariectomised rhesus monkeys has been
conducted to compare the effects of alendronate and odana-
catib [48]. The doses used in the study were chosen to mirror
the exposure to the drugs in postmenopausal women; however,
the odanacatib dose used resulted in 2 fold higher exposure.
QCT of the spine and hip revealed comparable effect of oda-
nacatib and alendronate at the spine and proximal hip, how-
ever, at the subtrochanteric femur, odanacatib increased
cortical thickness and bone mineral content (BMC) [48].
Similar results have been obtained in a study comparing the
effect of ONO-5334 and alendronate for 8 months in ovar-
iectomised monkeys [49].
2.3.1.2. Clinical investigations of odanacatib. The effect of a
single dose of odanacatib 50 mg is a >50% reduction in bone
resorption markers within 24 h [50]. The effect is reversible as
the effects on biochemical markers of bone turnover and BMD
are resolved after discontinuing odanacatib administration [51].
Absorption of odanacatib is not reduced by food but increased
by a high fat meal [50]. The half-life of odanacatib is 40e80 h
[50] and odanacatib is predominantly excreted unchanged in
the feces and urine, but some is metabolized by the liver
through the CYP3A pathway [52]. The pharmacokinetics of
odanacatib is unaffected by sex and age [51] and no significant
drugedrug interactions have been observed [53,54].
The phase 1 study included 44 healthy volunteers (36 men
and 8 postmenopausal women). The participants were treated
with ascending doses of odanacatib (2e600 mg). The study
demonstrated dose-dependent increases in serum levels of
odanacatib and decreases in bone resorption markers [55].
A global phase 2 study comprising 399 postmenopausal,
predominantly Caucasian women with osteopenia or osteo-
porosis (T-scores at spine or hip between 2 and 3.5)
investigated the effects of odanacatib 3, 10, 25, and 50 mg
weekly in comparison with placebo on bone turnover and bone
mineral density over 2 years [56]. This study revealed dose-
dependent decreases in the bone resorption marker u-cross-
linked N-terminal telopeptide of type 1 collagen/creatinine(NTx/Cr). uNTx/Cr was significantly reduced by 60% and
52% after 12 and 24 months, respectively, in women treated
with odanacatib 50 mg weekly. A Japanese phase 2 study
comprising 270 postmenopausal women and 17 men with
osteoporosis investigated the effects of odanacatib 10, 25, and
50 mg weekly in comparison with placebo on bone turnover
and bone mineral density over 1 year [57]. In this study uNTx/
Cr decreased by more than 60% after 1 month in patients
treated with odanacatib 25 and 50 mg weekly and remained at
this level throughout the 12 months study period. The effect of
odanacatib 50 mg compared with placebo was also investi-
gated in a male study comprising 292 predominantly Cauca-
sian men with osteoporosis or osteopenia in combination with
a prior vertebral fracture [58]. Less than 6% of the men were
hypogonadal, defined as s-total testosterone <250 ng/dL. In
this study uNTx/Cr decreased by 68% compared with placebo.
The bone formation marker procollagen type I N-terminal
propeptide (PINP) was dose-dependently decreased for the
first 6 months of the global phase 2 study and thereafter
gradually returned towards baseline levels. The maximum
decrease in the women treated with odanacatib 50 mg was
40% after 6 months. After 24 months the decrease was 20%. In
the Japanese study, sPINP decreased less rapidly, by approx-
imately 50% at month 6 and remained at this level for the rest
of the study period. Despite the similar effects on bone
resorption in the global and the Japanese phase 2 studies, the
effect on sPINP seems to follow a slightly different pattern in
the Japanese patients; the suppression of bone formation is less
rapid and more sustained in the Japanese patients. In the male
study the changes in sPINP were very similar to the changes
seen in the global phase 2 study; sPINP decreased initially by
approximately 40%, however, the decrease leveled of during
the course of the study and sPINP was only reduced by 16%
compared to placebo at the end of the study.
A fourth study, the special imaging study comprising 214
postmenopausal predominantly Caucasian women with
osteopenia or osteoporosis (BMD T-scores between 1.5 and
3.5) compared the effect of odanacatib 50 mg weekly with
placebo for 2 years on trabecular and cortical bone [59,60].
The effects on bone turnover seen in this study were similar to
the effects seen in the global phase 2 study.
The changes seen in the bone resorption marker; uNTx/Cr
are consistent across these studies in postmenopausal pre-
dominantly Caucasian and Japanese women and Caucasian
men. Treatment with odanacatib 50 mg weekly leads to a rapid
and sustained decrease in bone resorption of 50e70%. The
effect on bone formation may vary somewhat between
different populations however, at least in the studies
comprising predominantly Caucasian postmenopausal women
and men, bone formation is temporarily suppressed by 40%,
but the suppression is subsequently released and only slightly
below baseline after 2 years.
The global phase 2 study revealed dose-dependent in-
creases in BMD at the spine and hip. At the distal radius the
decrease in BMD seen in the placebo group was prevented.
The differences in BMD between women treated with oda-
nacatib 50 mg weekly and placebo for 24 months were 5.7% at
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femoral neck and trochanter, respectively and 2.9% at the
distal 1/3 radius [56].
BMD also increased dose-dependently in the Japanese
phase 2 study and the changes compared to baseline in patients
treated with odanacatib 50 mg weekly for 52 weeks were
þ5.9% at the lumbar spine, þ2.7%, þ2.3%, and þ4.2% at the
total hip, femoral neck and trochanter, respectively [57].
The effect on lumbar spine BMD was more prominent
among the Japanese patients; þ5.9% compared to þ3.5%
among Caucasian women after 12 months. The changes seen
at the hip sites were comparable between the two studies.
There may be more explanations for this difference between
the two studies. One possible explanation may be that Jap-
anese patients had more severe osteoporosis and lower BMD
at baseline. Lumbar spine BMD at baseline was 0.63 g/cm2
in the Japanese patients compared to 0.87 g/cm2 in the
Caucasian women. It has previously been demonstrated with
other antiresorptive treatments that low baseline BMD is
associated with an increased response to treatment [61,62].
If this is also true for odanacatib has not been investigated
yet. Another possible explanation may be the general dif-
ference between Caucasian and Japanese patients. The
Japanese have a lower body weight and height and also the
genetic background is different between these two
populations.
In the male study, BMD increased after treatment with
odanacatib for 2 years compared with placebo by 5.6% at the
lumbar spine and by 2.0%, 1.7%, and 2.1% at the total hip,
femoral neck and trochanter, respectively. The effect on
lumbar spine BMD was similar in the men as previously seen
in postmenopausal women, however, the effect on hip BMD
was less pronounced in the men. The difference seems to be
caused by a less pronounced increase in hip BMD in the
odanacatib treated men compared with the increase seen in the
odanacatib treated women in addition to a less pronounced
bone loss in the untreated men compared with untreated
women. These differences may be explained by the difference
in gender as the age-related changes in bone dimension and
composition are different between men and women [63], but
also by the fact that the vast majority of the men in the study
were eugonadal with serum levels of testosterone >250 ng/ml,
whereas the women were postmenopausal and estrogen defi-
cient. The baseline levels of uNTx/Cr and sPINP were higher
in the women in the global study than in the men included in
the male study and although these markers predominantly
reflect bone turnover in trabecular bone, these higher levels
may also indicate higher remodeling activity in cortical bone.
Bone biopsies have been obtained in the global phase 2
study (32 women, 4e7 in each of the five treatment groups)
and in the special imaging study (10 women, 5 odanacatib
treated and 5 placebo treated women). The biopsies demon-
strated no mineralization defects and no major effects on
activation frequency, bone formation or osteoclast covered
surfaces [56,59]. In the Long-term Odanacatib Fracture Trial
(LOFT) study 175 and 58 bone biopsies have been obtained
after 24 and 36 months, respectively. Histomorphometricanalyses are ongoing, however, histological evaluations
revealed no structural abnormalities [64].
The global phase 2 study has been extended several times.
The first extension was a one year extension enrolling 280
women. The women were within each of the original 5
treatment groups randomized to either odanacatib 50 mg or
placebo [65].
For the women continuing treatment with odanacatib 50 mg
uNTx/Cr remained suppressed (50%) through year 3, whereas
sPINP returned to baseline level (6%). BMD increased
continuously at all sites; þ2.3% at the lumbar spine, þ2.4%,
þ1.6%, and þ2.7% at the total hip, femoral neck and
trochanter, respectively, at the end of the third year [65].
The second extension of the global phase 2 study
comprised years 4 and 5 and included 141 women [66]. The
treatment allocations from the first extension was continued
for most participants, however, women treated with placebo or
odanacatib 3 mg weekly for the first 3 years were shifted to
treatment with odanacatib 50 mg weekly. The main purposes
of this second and the ongoing third extensions are long term
efficacy and safety. The number of women in each group in the
second extension is 13e16 and no statistical analyses have
therefore been performed. In women continuously treated with
odanacatib uNTx/Cr remained suppressed by 56% compared
to baseline at the end of year 5, whereas sPINP remained at
baseline level. The cumulative increases in BMD in women
treated with odanacatib 50 mg for 5 years were þ11.9% at the
lumbar spine and þ8.5%, þ9.8%, and þ10.9% at the total hip,
femoral neck and trochanter, respectively. BMD at the distal 1/
3 radius was unchanged; 0.3%.
A third extension comprising year 5e9 is currently
ongoing.
One of the aims of the first extension of the global phase 2
study was to study the effects of stopping treatment with
odanacatib. uNTx/Cr increased rapidly in women discontinu-
ing treatment after 2 years to þ50% and þ28% compared to
the original baseline after 1 and 12 months, respectively.
sPINP increased by 90% compared to the original baseline
after 6 months, but returned to the baseline level after
12 months. These changes in biochemical markers were re-
flected in rapid decreases in BMD to levels not different from
the original baseline after 12 months without treatment;
þ1.4% at the lumbar spine, 0.8%, þ2.3, 0.7% at the total
hip, femoral neck and trochanter, respectively. At the distal 1/3
radius BMD decreased to below the original baseline; 2.7%
[66].
The special imaging study generally confirmed the previ-
ously reported effects on bone turnover markers and BMD
[59]. Volumetric BMD was assessed by QCT and bone
structure parameters by high resolution peripheral quantitative
computed tomography (HRpQCT). Trabecular volumetric
BMD assessed by QCT at L1 was increased by 11.5%
compared with placebo and compressive strength estimated by
finite element analysis (FEA) was improved by 14.3%
compared with placebo after 2 years. At the hip, integral
volumetric BMD increased by 3.7%, 3.3%, and 6.0% at the
total hip, femoral neck and trochanter, respectively. The
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fall was 5.6% between the women treated with odanacatib
50 mg weekly and placebo. At the femoral neck cortical
thickness increased by 6.0% and cortical area by 4.9%,
whereas the total area and the volumetric cortical BMD were
unchanged.
FEA has been demonstrated to be a predictor of spine
[67,68], hip [69,70] and overall fracture risk [71]. The changes
seen with odanacatib may therefore suggest that treatment
with odanacatib reduces future fracture risk. The findings at
the femoral neck; increased cortical thickness, area and vol-
ume without concomitant changes in volumetric cortical BMD
or total femoral neck area suggest that treatment with odana-
catib leads to formation of new bone at the endosteal surface,
expanding the cortex into the cancellous bone. This increase in
cortical thickness is biomechanically advantageous. The QCT
applied in this study does not have a resolution high enough to
detect periosteal apposition in a similar magnitude as seen in
preclinical models [46].
HRqQCT at the radius and the tibia revealed increases in
total as well as trabecular and cortical volumetric BMD at both
sites in women treated with odanacatib 50 mg weekly for
2 years in comparison with placebo treated women. As seen
using QCT at the hip, treatment with odanacatib also increased
cortical thickness, cortical area and FEA estimates of bone
strength at the tibia and radius [60].
The LOFT (Longterm Odanacatib Fracture Trial) study
investigating the anti-fracture efficacy of odanacatib in post-
menopausal women. The LOFT study is a global, event-driven
phase 3 study that comprised 16,713 postmenopausal women.
The inclusion criteria were osteoporotic BMD at the hip (T-
score between 2.5 and4.0) or a prior radiographic vertebral
fracture in combination with low BMD at the hip (T-score be-
tween 1.5 and 4.0). The women were randomized to oda-
nacatib 50 mg weekly or placebo [72]. The study was stopped
after an interim analysis of the anti-fracture efficacy, when
approximately 70% of the target number of hip fractures had
occurred. The women had at that time participated in the study
for an average of 34.5 months. Women treated with the inves-
tigational drug were enrolled into the first extension where they
were maintained on the originally allocated investigational
drug and the study continued as double-blinded. This first
extension has recently been completed as all women have
received blinded treatment for 5 years. The women have been
enrolled into a second extension with the aim of investigating
the long-term effects and safety of odanacatib. All participants
receive ODANACATIB 50 mg weekly and the study is planned
to continue until all women have participated for 10 years.
Treatment with odanacatib resulted in significant reduced
risks of fractures. The risk of hip fractures was reduced by
47%, the risk of non-vertebral fractures by 23%, the risk of
clinical vertebral fractures by 72% and the risk of new/wors-
ening morphometric vertebral fractures by 54% [73,74].
For any new treatment of osteoporosis coming to a market
with many patients who have been treated previously, a rele-
vant question is if the drug can be used and will be beneficial
in patients previously treated with other anti-osteoporosistreatments. This question has for odanacatib been addressed
in the switching study comprising 243 postmenopausal pre-
dominantly Caucasian women previously treated with
alendronate for 3 years. Inclusion criteria in addition to the
previous alendronate treatment were osteoporosis at the hip or
osteopenia in combination with a prior fracture. The women
were randomized to odanacatib 50 mg weekly or placebo for
2 years [75]. In women stopping alendronate and continuing
on placebo markers of bone turnover; uNTx/Cr and sPINP
increased by approximately 30% and 90%, respectively,
already after 1 year and remained at this level throughout the
study period. In the women treated with odanacatib uNTx/Cr
decreased by approximately 15%, whereas sPINP increased by
more than 80% and was at a similar level as in the placebo
treated women. After 2 years, lumbar spine BMD remained
stable in the placebo treated women, but increased by 2.3% in
the odanacatib treated women, the difference between the two
groups was 2.6%. At the hip, BMD decreased in the placebo
treated women, but increased or remained stable in the oda-
nacatib treated women, the differences between the groups
being 2.7%, 2.7%, and 3.2% at the total hip, femoral neck and
trochanter, respectively. This study demonstrated that odana-
catib can be used after prior treatment with alendronate in
patients who still have low BMD and that treatment with
odanacatib leads to a further suppression of bone resorption,
while the suppression of bone formation seen after alendronate
is abolished. Bone mass improved significantly at all sites
compared with women discontinuing alendronate.
Treatment with odanacatib was generally well tolerated in
the phase 2 studies, the male study, the special imaging study,
and the study in women previously treated with alendronate
without differences in adverse events between the treatment
groups. In the extensions of global phase 2 study, participants
originally treated with placebo were switched to odanacatib
treatment. All study participants therefore received odanacatib
at some point during the original or extension studies and the
longest continuous placebo-controlled period in the trial was
3 years. More cases of urinary tract infections were reported
among women receiving odanacatib during years 4 and 5; 14%
versus 5% in the placebo treated women [66].
In the LOFT study, the incidence of adverse events (AEs)
and serious adverse events overall did not differ meaningfully
between the odanacatib and placebo groups [73,74]. There
were 271 deaths reported in the odanacatib group and 242 on
placebo (hazard ratio 1.13 [95% CI: 0.95, 1.35]); this numeric
imbalance in mortality did not appear related to a particular
reported cause of death. Prior to the start of the study, certain
adverse events of interest were identified for adjudication:
morphea-like skin lesions, systemic sclerosis, serious respi-
ratory infections, and osteonecrosis of the jaw, atypical
femoral shaft fractures, delayed fracture unions, atrial fibril-
lation and major adverse cardiovascular events. Adjudicated
morphea-like skin lesions occurred in 12 patients treated with
odanacatib compared to 3 patients in the placebo group. These
skin lesions resolved or improved after discontinuation of the
study drug. Adjudicated atypical femoral shaft fractures were
reported for 5 patients in the odanacatib group and not
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observed in systemic sclerosis, serious respiratory infections,
or delayed fracture unions. There were no cases of osteonec-
rosis of the jaw. Major cardiovascular events overall were
generally balanced; however, there were numerically more
adjudicated strokes with odanacatib than with placebo [73,74].
The evaluation of these adjudicated events from the base and
extension studies is ongoing.Fig. 1. Results from the clinical trials investigating the cathepsin K inhibitors;
Odanacatib and ONO-5334. The columns represent the difference in BMD
between the actively treated participants and the placebo treated participants.
Global ph 2: The global phase 2 study [56], Male: The male study [58], Spec
Imag: The special imaging study [59], Japan ph 2: The Japanese phase 2 study
[57], LOFT: The Long-term Odanacatib Fracture Trial [74], ONO-5334:
ONO-5334 300 mg daily, ALN: Alendronate 70 mg weekly, ONO-5334 and
ALN are from the OCEAN study [80].2.4. Cathepsin K inhibitors that have been in clinical
development
2.4.1. Balicatib
Balicatib is a specific inhibitor of cathepsin K. Balicatib is
highly selective against other non-K cathepsins in enzymatic
assays, but because it accumulates in the acidic lysosomes
(lysosomotropic) the selectivity is compromised over time
[43]. The clinical effects of balicatib were investigated in a
clinical study comprising 675 postmenopausal women with
osteopenia or osteoporosis comparing 5, 10, 25 and 50 mg
balicatib daily with placebo for 12 months. uNTx/Cr was
decreased by 55% in the women treated with 50 mg balicatib,
whereas sPINP was unaffected. BMD at the lumbar spine and
total hip increased by 4.5% and 2.3% after 12 months,
respectively [76]. Seven of 709 women treated with balicatib,
primarily the 50 mg dose, developed morphea-like skin lesions
which resolved after stopping the treatment and the lesions
were therefore considered related to balicatib [77]. Further
clinical development of balicatib was stopped.
2.4.2. ONO-5334
ONO-5334 is a low-molecular-weight synthetic inhibitor of
cathepsin K. In vitro studies have demonstrated that ONO-
5334 is a potent, specific and non-lysosomotropic inhibitor
of cathepsin K [78]. The clinical effects of this compound
have been investigated in a clinical trial, the ONO-5334
cathepsin K inhibitor European study (OCEAN) comprising
285 postmenopausal, Caucasian women with osteoporosis
without suppressed bone turnover. The women were random-
ized to ONO-5334 50 mg twice daily, 100 mg or 300 mg daily,
alendronate 70 mg weekly or placebo for 2 years [79]. Bone
turnover and BMD was dose-dependently affected by ONO-
5334. uNTX/Cr was suppressed by 63% and 67% in the
ONO-5334 300 mg and the alendronate treated women,
respectively, after 12 months and remained at this level for the
rest of the treatment period. sPINP decreased by 27% and 64%
in the ONO-5334 300 mg and the alendronate treated women,
respectively, after 12 months. sPINP remained suppressed in
the ALN treated women, whereas sPINP returned to baseline
level at month 24 in the ONO-5334 treated women. BMD
increased after 2 years in women treated with ONO-
5334 300 mg by 6.7%, 3.4% and 3.7% at the lumbar spine,
total hip and femoral neck, respectively. In response to
Alendronate BMD increased 6.3%, 4.2%, and 2.9% at the
lumbar spine, total hip and femoral neck, respectively. The
patients were followed for an additional 2 months off treat-
ment. uNTx/Cr increased to approximately 40% abovebaseline level in women stopping treatment with ONO-
5334 300 mg, whereas uNTx/Cr remained suppressed in the
women stopping alendronate. sPINP increased by approxi-
mately 50% after stopping ONO-5334 300 mg, but remained
suppressed in the women stopping alendronate. ONO-5334
was generally well tolerated [79,80].
In a subgroup of 147 women in the OCEAN study QCT of
the spine and hip was performed. In women treated for two
years with ONO-5334 300 mg integral, cortical, and trabecular
volumetric BMD at lumbar vertebrae L1 and L2 increased by
10.5%, 7.1%, and 13.4%, respectively. At the total hip inte-
gral, cortical and trabecular volumetric BMD increased by
6.2%, 3.4%, and 14.6%, respectively. These changes were
similar to the changes seen after two years treatment with
alendronate. Bone volume or cortical thickness did not in-
crease after ONO-5334. Finite element analyses of bone
strength were not reported [81].
The effects of the ONO-5334 300 mg daily dose were
similar to the effects seen after ODANACATIB 50 mg weekly
(Fig. 1). The increase in aBMD at the spine and the increases
in volumetric BMD were numerically greater. This may be
caused by the fact that women with low bone turnover, defined
as uCTX/Cr <200 ug/mmol, were excluded from the OCEAN
study. No additional trials investigating ONO-5334 is regis-
tered at www.clinicaltrials.gov.2.5. DiscussionPycnodysostosis is characterized by high bone mass, but
also bone fragility. This is the outcome of lifelong lack of
cathepsin K. Animal and human studies have so far only
indicated that inhibition of cathepsin K leads to increased bone
mass across species [44,46] and reduced fracture risk in
postmenopausal women [74]. There have been no indications
of increased bone fragility so far. However, it will be important
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in relevant patient populations.
Inhibition of cathepsin K leads to suppression of bone
resorption and this is followed by suppression of bone for-
mation, however, only temporarily. In the global odanacatib
phase 2 study, bone formation markers had returned to base-
line after 2 years treatment. This suggests an uncoupling of
bone resorption and bone formation. This uncoupling is not
absolute at trabecular bone surfaces as bone formation is not
seen without previous bone resorption, but relative because the
bone resorption is incomplete due to inhibition of cathepsin K.
The extension of resorptive surfaces is unchanged but
resorption depth is reduced [82]. The number of osteoclasts is
stable or increased and presumably sending the usual signals
to the osteoblasts for them to start laying down new bone, and
evaluated by biochemical markers of bone turnover, the os-
teoblasts maintain their usual activity after a temporary
reduction during the first year of treatment (Fig. 2). This
would explain the continued increase in BMD seen both at the
spine and hip sites, however, if this is the exact mechanism of
action remains to be demonstrated by a complete histo-
morphometric reconstruction of the remodeling sequence [64].
The monkey studies demonstrated bone formation due to bone
modeling at periosteal surfaces of the long bones [46]. If this
mechanism is also relevant in postmenopausal women and
elderly men remains to be demonstrated. QCT analyses of the
hip in postmenopausal women demonstrated increased cortical
thickness and cortical mass, however, the total bone area was
unchanged, suggesting that bone was added at the endocorticalFig. 2. Simplified cartoon of the effect of different treatment modalities on bone rem
lines indicate reduction, double lines indicate increase. BDGF: bone derived growth
remodeling: Osteoclast recruitment and activation are stimulated by RANKL prod
clastokines and indirectly by BDGFs released during bone resorption. Osteocytes c
by the osteocytes. Bisphosphonates: Osteoclasts become apoptotic and stop produ
formation is therefore not stimulated. Parathyroid hormone: Osteoblasts number a
Sclerostin production is reduced and this may reduce RANKL production by the
osteoclasts, is inhibited, and therefore clastokines are still produced and bone forma
continues. RANKL production by the osteocytes are reduced due to the lack of stsurface [59]. Unfortunately, the resolution of QCT is not high
enough to detect bone formation at periosteal surface, even if
it was at the same magnitude as seen in the monkeys. If this
mechanism of bone formation due to bone modeling at the
periosteal surfaces is also relevant in postmenopausal women
and elderly men treated with inhibitors of cathepsin K, then
this may be partly responsible for the return of the markers of
bone formation to baseline.
The antifracture efficacy of odanacatib has only been
published in meeting abstracts so far [74], but seems to be
similar to other antiresorptive treatments [83e85]. The
reduction in clinical vertebral and hip fractures is impressive,
72% and 47%, respectively; however, the reduction of non-
vertebral fractures is only 23%. This is as good as the best
of the available antiresorptive treatments [83e85]. The pivotal
teriparatide trial demonstrated a 50% reduction of non-
vertebral fractures [16] and a posthoc analysis suggested that
this effect increased with increasing duration of treatment
[86]. The sparing of bone formation during treatment with
odanacatib has lead to expectations of an improved effect on
non-vertebral fractures. This does not seem to be the case after
34.5 months of treatment. The teriparatide trial suggested that
prevention of non-vertebral fractures needs treatment for a
longer duration than for example prevention of vertebral
fractures and it will therefore be interesting to see the reduc-
tion in non-vertebral fractures after 5 years of treatment with
odanacatib. Another factor that has increased the expectations
of an improved effect towards non-vertebral fractures is the
increased cortical area and thickness at the femoral neckodeling. Arrows indicate stimulation, blocked lines indicate inhibition, dotted
factors. RANKL: receptor activator of nuclear factor kappa-B ligand. Normal
uced by osteoblasts and osteocytes. Osteoclasts stimulate bone formation by
ontrol bone formation by sclerostin. Sclerostin stimulates RANKL production
cing clastokines and resorbing bone and thereby releasing BDGFs and bone
nd activity are stimulated and so is RANKL production from the osteoblasts.
osteocytes? Cathepsin K inhibitors: Resorption, but not the viability of the
tion maintained. Sclerostin antibody: Sclerostin is inhibited and bone formation
imulation by sclerostin.
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treatment [59]. These findings suggest that bone is added at the
endocortical surface. Thickening of the cortex is advantageous
from a mechanistic point of view and the estimated strength
towards a sideward fall was increased by 5.6% compared with
placebo. Similar investigations have not been done at the
femur or forearm; however, studies in monkeys have demon-
strated increases in cortical thickness at the proximal femur
[46].
The suppression of bone resorption without continued
suppression of bone formation has also lead to expectations of
a reduced risk of osteonecrosis of the jaw and atypical frac-
tures. The exact mechanisms underlying these very rare side
effects to treatment with bisphosphonates and denosumab are
not known. Recent investigations suggest that it is not
bisphosphonate located in the bone, but bisphosphonate in the
circulation that is associated with osteonecrosis of the jaw
[87]. This suggests that osteonecrosis of the jaw is primarily
caused by an effect of bisphosphonate on the osteoblast. No
cases of osteonecrosis of the jaw have been reported so far in
patients treated with odanacatib. The mechanism underlying
atypical femur fractures is still unknown. Five cases of atyp-
ical femur fractures were reported in odanacatib treated
women in the LOFT trial and no cases among placebo treated
women.
The ONO-5334 compound has a short half-life and there-
fore has to be taken daily. odanacatib has a half-life of
40e80 h can therefore be taken weekly. Studies comparing
compliance between daily and weekly alendronate and
risedronate has demonstrated that weekly dosing increases
compliance compared to daily dosing [88]. Another quality of
odanacatib that potentially can improve compliance is that
odanacatib can be taken with or without food [50].
Morphea was seen in 12 women treated with odanacatib
compared to 3 women in the placebo group. The lesions
resolved or improved after stopping odanacatib and in
response to standard treatment for morphea. Adjudication of
cardiovascular events is still ongoing, however, based on the
clinical studies investigating the specific and non-
lysosomotropic cathepsin K inhibitors; odanacatib and ONO-
5334, these treatments seem well-tolerated but more cases of
atypical femur fractures and morphea were seen in women
treated with odanacatib compared with the untreated women.
3. Inhibition of sclerostin3.1. SclerostinOsteocytes are terminally differentiated osteoblasts which
become embedded in newly formed bone matrix and start
producing sclerostin. Sclerostin is encoded by the SOST gene
and is primarily secreted by osteocytes and in significantly
smaller amounts by cementocytes and mineralized hypertro-
phic chondrocytes [89]. Sclerostin binds to lipoprotein related
peptide (LRP) 5/6 and thereby inhibits LRP5/6 from binding
to the frizzled receptor and activating the Wnt pathway [90].
Wnt is a combination of int and Wg and stands for Wingless-related integration site [91]. The Wnt pathway has two
different tracks; canonical, which results in stabilization of b-
catenin, and non-canonical, which is independent of b-catenin
[92]. Activation of the Wnt canonical pathway induces
translocation of b-catenin to the nucleus of the osteoblasts and
subsequently gene transcription that stimulates bone formation
through stimulation of osteoblast differentiation, proliferation
and survival [93]. The secretion of sclerostin is regulated by
several factors, including estrogen, PTH and mechanical
loading [94e100].
Individuals without endogenous sclerostin production due
to loss of function mutations in the SOST gene have sclero-
steosis [101,102]. Sclerosteosis is inherited as an autosomal
recessive disorder, characterized by immeasureable levels of
sclerostin and normal bone mass at birth, but progressive bone
thickening throughout the first decades of life. The condition
tends to stabilize in young adulthood [103]. The increased
bone mass is associated with a very low risk of fractures
[102,104e106]. Other characteristics of the disorder are tall
stature, syndactyly and skull enlargement with the risk of
cranial nerves being entrapped and paralyzed, leading to for
example facial palsy. Some patients develop increased intra-
cranial pressure [105]. Van Buchem disease is caused by a
mutation in the regulatory region of the SOST gene and
generally presents as a milder form of sclerosteosis, charac-
terized by high BMD, normal height, but without syndactyly
[107,108]. Bone biopsies from patients with sclerosteosis
show increased bone formation and normal bone architecture
[109,110]. Examination of the cortical bone using quantitative
backscattered electron imaging have demonstrated that the
matrix mineralization density distribution was shifted towards
lower matrix mineralization compared to the normal reference
and increased content of proteoglycans, changes that may be
explained by the increased bone formation rate [111]. Similar
alterations were seen in bone samples from SOST knockout
mice (see below).
Interestingly, heterozygous carriers of the SOST mutations
have high bone mass but none of the complications seen in the
patients homozygous for the mutations [104].
Female and male mice without a functioning SOST gene
appear normal with a morphologically normal skeleton.
Compared to normal littermates BMD was increased by 50%
and microCT examination revealed increased bone volume in
trabecular as well as cortical bone compartments in the mice
without sclerostin. Histomorphometric analyses revealed
increased bone formation rate at trabecular, endocortical and
periosteal bone surfaces without changes in bone resorption.
Mechanical testing of vertebrae and femur demonstrated 2e3
fold increased strength [112]. In order to continuously increase
bone mass, the animals need to establish a positive calcium-
and phosphorus balance. This is accomplished by increased
serum concentrations of 1.25 dihydroxy vitamin D3 and
decreased concentrations of fibroblast growth factor (FGF)-23
[113]. Mice without endogenous SOST production have been
demonstrated to have accelerated fracture healing [114,115].
Sclerostin has been suggested to be involved in the skeletal
response to physical loading [116] and SOST knock-out mice
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expression of sclerostin in cartilage, it has be speculated if
lack of sclerostin would affect the development of osteoar-
thritis, however, the evidence so far is conflicting [118,119].3.2. Preclinical models of sclerostin inhibitorsThe effects of inhibition of sclerostin by antibodies have
been examined in animal models.
Six-month old female rats were ovariectomised or sham
operated. Thirteen months later at the age of 19 months, the
ovariectomised rats were randomly assigned to 5 weeks
treatment with a sclerostin antibody (Scl-Ab) 25 mg/kg twice
weekly or placebo [120]. BMD at the lumbar spine and the
femur-tibia increased by 26% and 17%, respectively, in the
Scl-Ab treated rats. Serum osteocalcin increased almost 3 fold
during the first week of treatment and subsequently declined,
however, remained elevated 2 fold throughout the treatment
period.
Histomorphometric analyses of both cancellous and
cortical bone revealed that bone volume was increased in both
compartments. Furthermore, bone formation indices were
markedly elevated on trabecular, periosteal, endocortical and
intracortical surfaces. Osteoclast covered surface was reduced
compared to placebo treated animals and similar to sham
operated animals. Finally, bone strength measured at a verte-
brae and the femoral shaft was increased above the bone
strength seen in sham operated rats [120]. A similar study was
done in aged, gonad-intact male rats. Treatment with Scl-Ab
for 5 weeks resulted in increases in BMD and bone strength
and histomorphometry revealed unchanged bone resorption,
but increased bone formation at all surfaces [121]. A 26 week
study was done in 6 months old female rats, which were
ovariectomised 2 months previously. Bone mass and strength
increased progressively throughout the study period. Histo-
morphometric analyses revealed that bone formation rate
peaked after 6 weeks and thereafter declined towards baseline,
whereas bone resorption remained suppressed throughout the
26 weeks [122]. The effects of previous or concomitant
treatment with alendronat were investigated in 10 months old
ovariectomised rats. Neither pre-treatment nor pre- and
concomitant treatment with alendronate affected negatively
the outcome of 6 weeks Scl-Ab treatment [123].
A short-term study has been conducted in female, gonad-
intact cynomolgus monkeys [124]. The monkeys were ran-
domized to Scl-Ab 3, 10, or 30 mg/kg or placebo monthly for
2 months. BMC and BMD increased dose-dependently
(11e29%), bone strength was increased in the monkeys
treated with the highest dose and histomorphometric analyses
of bone samples revealed increased bone formation on
trabecular, periosteal, endocortical and intracortical surfaces.
Bone formation markers (PINP and osteocalcin) increased
dose-dependently whereas s-C-telopeptide of type 1 collagen
(CTX) decreased temporarily, suggesting an uncoupling of
bone formation and resorption [124].
Studies in rats and monkeys have also demonstrated that
inhibition of sclerostin can lead to bone formation onquiescent surfaces; modeling based bone formation [125] in
addition to the positive balance at the remodeling sites.
Osteocytes control the adjustment of the skeleton to me-
chanical loading through secretion of sclerostin. Hind limb
suspension and spaceflight are methods used for investigating
immobilization in animal models. Inhibition of sclerostin has
been demonstrated to prevent bone loss under these conditions
in mice [126]. Furthermore, healing of fractures are acceler-
ated in rats and monkeys treated with sclerostin antibodies
[127,128].
No adverse effects have been seen in the preclinical studies.3.3. Sclerostin inhibitors
3.3.1. Romosozumab
Romosozumab is a humanized monoclonal antibody IG2
type against sclerostin. Absorption of subcutaneously admin-
istrated romosozumab is 50e70% [129]. The half-live of
romosozumab is 6e7 days [129,130]. Clearance of romoso-
zumab was decreased with administration of higher doses and
a non-linear pharmacokinetic profile was observed. This is a
well-known phenomenon with monoclonal antibodies [131].
Bone formation markers increased dose-dependently with a
maximum 3e4 weeks after administration of a single dose.
Administration of romosozumab 10 mg/kg subcutaneously
lead to an increase in sPINP of 184%. Bone resorption
measured by sCTX decreased by 54% within 2 weeks.
Markers of bone formation and resorption returned to baseline
8 and 6 weeks after administration of a single dose, respec-
tively [129]. Approximately 10% of individuals administered
romosozumab develops antibodies against romosozumab. The
antibodies are predominantly neutralizing and the clinical
relevance of these antibodies is currently not known. Romo-
sozumab was generally well tolerated; however, more injec-
tion site reactions were seen among subjects receiving
romosozumab than placebo [129].
3.3.1.1. Clinical efficacy. The phase I single dose study
including healthy postmenopausal women and men demon-
strated increases in BMD at the spine and hip of up to 5.3% and
2.8%, respectively, after a single injection of romosozumab
[129]. The phase I multiple dosing study included 32 healthy
postmenopausal women who were treated with romosozumab
1e2 mg/kg every other week for or 2e3 mg/kg every 4 weeks
and 16 healthy men who were treated with romosozumab 1 mg/
kg every 2 weeks, 3 mg/kg every 4 weeks or placebo for
8e10 weeks [130]. sPINP increased by 66e147%, sCTX
decreased by 15e50% and lumbar spine BMD increased by
4e7% reaching a maximum 8e10 and 14e16 weeks after the
last injection in women and men, respectively [130].
The effect of romosozumab in women with low bone mass
has been investigated in a phase 2 study comprising 419
postmenopausal, primarily Caucasian women with low bone
mass defined as BMD T-scores at the spine or hip below 2,
but above 3.5 at all sites. The women were randomized to
12 months treatment with romosozumab 70 mg, 140 mg or
210 mg subcutaneously every month, 140 mg or 210 mg
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weekly, teriparatide 20 mg subcutaneously daily or placebo
[132].
Treatment with romosozumab 210 mg monthly lead to a
rapid increase in sPINP; þ91% after 1 month. The increase
leveled off over the following months and sPINP had returned
to baseline level after 6 months. At the end of the 12 month
treatment period sPINP was 20% below baseline level. Bone
resorption was measured by sbCTX, which decreased by 41%
one week after administration of the first dose of romosozu-
mab 210 mg. This decrease leveled off within the first
2 months; however, a second decrease in sbCTX was seen
during the last 6 months of the treatment period and at the end
of the study sbCTX was reduced by 26%. Bone turnover
markers were not measured in women treated with alendronate
or teriparatide during the first 3 months of the study. Between
month 3 and 12 bone markers were changed as expected;
markers were suppressed with alendronate treatment (sPINP;
64% and sbCTX; 66%) and increased with teriparatide
treatment (sPINP; þ84% and sbCTX; þ80%).
BMD at the lumbar spine increased by 11.3% in women
treated with the romosozumab 210 mg monthly dose (Fig. 3).
Changes seen with placebo, alendronate and teriparatide were
0.1%, þ4.1%, and þ7.1%, respectively. At the total hip
BMD changed by 4.1%, 1.9%, 1.3% and 0.7% in women
treated with romosozumab 210 mg monthly, alendronate
weekly, teriparatide daily and placebo, respectively [132].
The effects of romosozumab were also examined using
QCT imaging of the spine and hip, only the results for the
women treated with romosozumab 210 mg monthly, ter-
iparatide 20 ug daily and placebo have been reported [133].
Integral volumetric BMD increased significantly more with
romosozumab than teriparatide or placebo at both the lumbar
spine and total hip. Trabecular volumetric BMD increased
similarly with romosozumab and teriparatide at the spine,
however, at the hip trabecular volumetric BMD increased
10.8% with romosozumab compared with 4.2% withFig. 3. Results from the clinical trials investigating the sclerostin antibodies;
romosozumab and blosozumab. The columns represent the changes seen after
12 months. The left four sets of columns are from the romosozumab phase 2
study [132] and the right two sets of columns are from the blosozumab phase 2
study [137]. ROMO 210 mg Q4W: Romosozumab 210 mg every 4 weeks,
TPTD: Teriparatide 20 mg daily, ALN: Alendronate 70 mg weekly, PCB:
Placebo. BLOSO 270 mg Q2W: Blosozumab 270 mg every 2 weeks.teriparatide. Cortical volumetric BMD at the total hip
increased with romosozumab; þ1.1%, but not with teripara-
tide; 0.9%.
Romosozumab was generally well tolerated, however, in-
jection site reactions were observed more frequently with
romosozumab than with placebo. Antibodies against romoso-
zumab were found in 20% of the romosozumab treated
women, 3% were neutralizing [132].
This study has been extended several times and the out-
comes after the 2nd and 3rd year have been presented [134]. In
the second year, women were continued on the originally
assigned treatment and dose. In the third year women were re-
randomized within each group to placebo or denosumab.
During the second year, BMD continued to increase. After
2 years, BMD at the spine and total hip had increased by
15.7% and 6.0%, respectively, in women treated with romo-
sozumab 210 mg monthly. BMD in the spine and total hip in
women, who were treated with denosumab during the third
year, continued to increase and the total increases over the
3 years were 19.4% and 7.1%, respectively. Women, who
stopped romosozumab and were treated with placebo during
the third year, lost bone mass and BMD returned towards
pretreatment levels [129,134].
The bone formation marker sPINP remained below baseline
during the second year of treatment with romosozumab. sPINP
decreased in the women transitioning to denosumab in year 3
and returned to pretreatment level in women transitioning to
placebo. The bone resorption marker sCTX remained below
pretreatment level during the second year, decreased further in
women transitioning to denosumab, but increased above pre-
treatment levels in women transitioning to placebo. sCTX
returned towards pretreatment levels towards the end of year 3.
The study is still ongoing and more information about long-
term effects of romosozumab, including sequential treat-
ment, is to come.
Furthermore, the clinical effects of romosozumab including
the anti-fracture efficacy are currently being investigated in
ongoing phase 3 studies (www.clinicaltrials.gov).
3.3.2. Blosozumab
Blosozumab is a humanized immunoglobulin G4 (IgG4)
anti-sclerostin monoclonal antibody [135]. Bone formation
markers (osteocalcin, bone alkaline phosphatase and P1NP)
are increased dose-dependently with a maximum 3e4 weeks
after administration of a single dose of blosozumab to healthy
postmenopausal women. Administration of blosozumab
750 mg intravenously or 150 mg subcutaneously lead to in-
creases in sPINP of 300% and 60%, respectively. sCTX
decreased by approximately 50% and 35% within 2 weeks
after administration of 750 mg intravenously or 150 mg sub-
cutaneously, respectively. Markers of bone formation and
resorption returned to baseline 6e8 and 4 weeks after
administration of a single dose, respectively [136]. Antibodies
against blosozumab were detected in 23% after a single in-
jection of blosozumab and in 36% after multiple administra-
tions. These antibodies did not affect pharmacodynamics. A
common adverse event in the phase I studies were injection
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limiting [136].
3.3.2.1. Clinical efficacy. The phase I study included healthy
postmenopausal women, who were treated with single or
multiple injections of blosozumab subcutaneously or intrave-
nously. Treatment with a single dose of 150 mg subcutane-
ously increased lumbar spine BMD 1.5% after 8 weeks.
Multiple dosing; 270 mg every other week for 8 weeks,
increased spine BMD by 5.6% [136].
The clinical efficacy of blosozumab has been investigated
in a phase 2 study comprising 120 Caucasian and Japanese
postmenopausal women between 45 and 85 years. Inclusion
criterion was lumbar spine BMD T-score between 2 and
3.5. Average lumbar spine and femoral neck BMD T-scores
were 2.8 and 2.1, respectively. The women were ran-
domized to blosozumab 180 mg every 4 weeks, 180 mg every
2 weeks or 270 mg every 2 weeks or placebo for 52 weeks
[137].
Treatment with blosozumab 270 mg every 2 weeks lead to a
rapid increase in sPINP of approximately 150% compared to
baseline line after 1 month. The increase leveled off over the
following months but was still above baseline level after
6 months. At the end of the 12 month treatment period sPINP
had returned to the baseline level. Bone resorption was evalu-
ated by sCTX, which decreased by approximately 45% two
weeks after administration of the first dose of blosozumab
270 mg. The decrease leveled off within the first 3 months;
however, a second decrease in sCTX was seen during the last 6
months of the treatment period and at the end of the study sCTX
was reduced by approximately 15% compared to baseline.
BMD at the lumbar spine increased by 17.7% after
12 months in the women treated with the blosozumab 270 mg
every 2 weeks. BMD at the lumbar spine decreased by 1.6% in
women treated with placebo. At the total hip BMD changed by
þ6.7% and 0.7% in women treated with blosozumab 270 mg
every 2 weeks and placebo, respectively [137].
Blosozumab was generally well tolerated, however,
23e40% of the women receiving blosozumab reported injec-
tionesite reactions compared to 10% of women receiving
placebo. Thirty-five percent of women treated with blosozu-
mab developed anti-blosozumab antibodies. In one patient the
antibody seemingly affected the BMD response negatively
[137].
The women were followed for an additional year after
completing the 52 weeks intervention [138]. Bone formation
markers remained at a level not significantly different from
baseline. sCTX increased after stopping blosozumab and was
not different from placebo treated women 1 year after stopping
blosozumab. BMD at both the spine and hip decreased after
stopping blosozumab. One year after stopping blosozumab
lumbar spine BMD was still 6.9% above baseline and 8.2%
higher than placebo. BMD at the total hip was 3.9% above
baseline and 5.2% higher than in women previously treated
with placebo [138].
Interestingly, the serum concentration of sclerostin
increased rapidly during the first weeks of treatment withblosozumab and continued to increase albeit at a slower pace
to the end of the intervention period. The concentration
decreased rapidly to baseline levels after stopping treatment
[138]. The concentration of free sclerostin in serum was below
detection limits. The high and increasing concentration of
sclerostin in serum during treatment is therefore most likely
primarily composed of blosozumabesclerostin complexes.
No difference in adverse events was noted between groups,
except for more injection site reactions in the women treated
with blosozumab [137]. The phase 3 program is currently at
hold due to these injection site reactions (personal
communication).3.4. DiscussionShort-term studies of antibody mediated inhibition of
sclerostin in rats and monkeys have consistently shown stim-
ulation of bone formation and reduced or unaltered bone
resorption. Histomorphometric analyses of bone from rats and
monkeys confirm that inhibition of sclerostin leads to stimu-
lation of formation at trabecular, endocortical, cortical and
periosteal surfaces, while resorption is reduced or maintained
[120,125].
Clinical studies in postmenopausal women investigating
two different antibodies against sclerostin have shown that
markers of bone formation are increased markedly within the
first months of treatment and then return towards baseline after
6 months and drop below baseline after six months treatment
[132,137]. Markers of bone resorption show an interesting
sequence of changes; the markers decrease rapidly upon
initiation of treatment, at 2 months resorption markers have
returned to baseline and from 3 months they slowly decrease
(romosozumab) or remain at the baseline level (blosozumab)
[132,137]. These changes in markers of bone turnover suggest
uncoupling of resorption and formation.
For both sclerostin antibodies in clinical development, this
phase of uncoupling seems to be limited. For romosozumab, it
lasts approximately 6 months and markers of both formation
and resorption thereafter declines below baseline, mirroring
antiresorptive treatment. For blosozumab, the uncoupling lasts
a little longer, but then the markers decline, resorption below
baseline, and formation to baseline. A study in ovariectomised
rats have also shown that the temporary nature of the changes
seen in biochemical markers of bone resorption and formation
after initiation sclerostin inhibition. In the same study histo-
morphometric analyses were also performed at different time
points. Interestingly, although markers of bone resorption after
an initial reduction returned to baseline, bone resorption,
evaluated in the biopsies, was still markedly reduced. On the
other hand, the reduction in bone formation markers seen after
the initial increase was followed by a reduced bone formation
activity in the bone [139].
In addition of the uncoupling of bone resorption and for-
mation seen at bone remodeling sites, animal studies have also
suggested that at some surface bone formation takes place on
quiescent surfaces. Short-term studies in rats and monkeys
have demonstrated that initiation of treatment with sclerostin
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with remodeling-based formation, suggesting that the bone
formation period is extended, and markedly increases
modeling-based formation [125]. The increase seen in
modeling-based formation seems to be a more prominent
feature with inhibition of sclerostin than with teriparatide
treatment [140,141].
Changes in serum levels of sclerostin are reported in the
phase 2 blosozumab study [138]. The baseline levels of scle-
rostin are not mentioned in the publication, however, the
concentration raises markedly, probably >100 fold. Serum
concentrations of free sclerostin are immeasurable and the
measured sclerostin is therefore most likely bound by sclero-
stin antibodies. On the basis of these changes in s-sclerostin, it
is likely that the stimulated bone formation phase is limited by
the response of the osteocytes; increased release of sclerostin
and thereby overcoming the inhibition by sclerostin anti-
bodies. It is more difficult to explain the changes seen in bone
resorption. Osteocytes are the major source of RANKL and
thereby stimulation of osteoclast recruitment and activity.
Sclerostin produced by the osteocytes stimulates through in-
hibition of the Wnt pathway their own release of RANKL
[142]. Inhibition of sclerostin may therefore lead to a decrease
in RANKL release and thereby in osteoclast number and ac-
tivity (Fig. 2). As the osteocyte increases the production of
sclerostin in response to the antibody treatment, RANKL
release is resumed. The second phase with decline of both
resorption and formation could represent a phase of reestab-
lishing the coupling between resorption and formation, and
formation is therefore reduced secondarily to a reduction in
resorption.
The increases in BMD with sclerostin antibodies are larger
than the increases seen with teriparatide. This difference may
be because of a stronger stimulation of bone formation with
sclerostin antibodies than with teriparatide, however, the in-
creases in sPINP seem similar between the women treated
with romosozumab and teriparatide, in fact the increased is
sustained for at least 12 months with teriparatide. The
important difference is therefore more likely the effect on bone
resorption. With teriparatide, resorption and formation are still
coupled and bone resorption increases secondarily to the in-
crease in bone formation. With sclerostin antibodies, resorp-
tion and formation are uncoupled and bone resorption is
decreased. If this difference in the mechanisms of action is
going to be reflected in fracture prevention remains to be seen.
The anti fracture efficacy of romosozumab is currently being
investigated and the outcome of these trials will determine the
role of this treatment in the management of osteoporosis.
Interestingly, the extensions of the phase 2 studies revealed,
like previously shown for teriparatide, that when anabolic
treatment is stopped, bone is rapidly lost. No follow-up
treatment was investigated in the phase 2 blosozumab study,
but in the phase 2 romosozumab study, women who had
received 2 years of treatment with romosozumab was transi-
tioned to either denosumab or placebo. In the women treated
with denosumab a further increase in bone mass is seen. This
corresponds to what has previously been shown withteriparatide and suggests that anabolic treatments should al-
ways be used in the context of sequential therapy [143].
Romosozumab and blosozumab were generally well toler-
ated in the phase 2 studies, however, injection site reactions
have been seen with both romosozumab and blosozumab. The
reactions were generally mild and not recurrent. The reactions
were seen in approximately 10% of patients treated with
romosozumab, but in up to 40% of women treated with blo-
sozumab. These reactions have put the clinical development of
blosozumab on hold.
From a theoretical point of view other potential safety is-
sues related to sclerostin inhibition have been considered. The
Wnt pathway is found in many organ systems and generally
manipulating this pathway may provide a risk of non-target
effects or even adverse events. Sclerostin is, however, almost
exclusively produced by osteocytes in the bone environment
and extra skeletal adverse effects are therefore not anticipated.
It has, however, been reported that production of sclerostin can
be found in calcifying vascular tissue [144,145]. It is currently
unknown if sclerostin is actively involved in vascular calcifi-
cation or merely a marker. Patients with genetically deter-
mined reduced or absent sclerostin have not been found to
have increased risk of cardiovascular disease [108,109].
Furthermore, mice without the SOST gene show no sign of
vascular calcification and renal insufficient mice with phar-
macologically reduced serum sclerostin seem to be protected
against vascular calcification [112]. Another concern in rela-
tion to activation of the Wnt pathway is that it may increase
the risk of cancer [146], however, the patients with sclero-
steosis or van Buchem disease have had absent or low levels of
sclerostin throughout life and no increase in cancer has been
reported among these patients [108,109]. Furthermore, no
cases of cancer or osteosarcomas were seen in animal studies.
Finally, there has been some concern that inhibition of
sclerostin could accelerate the development of osteoarthritis.
Sclerostin is produced by mineralizing chondrocytes and
decreased expression of sclerostin has been demonstrated in
damaged cartilage in mice and sheep [147] and an
osteoarthritis-like phenotype has been reported in mice after
activation of the Wnt pathway [148]. The results regarding
development of posttraumatic osteoarthritis in SOST knock-
out mice conflicting [118,119]. The ongoing phase 3 studies
will reveal if this is relevant in postmenopausal women.
4. General discussion
The two new potential treatments of osteoporosis; odana-
catib and romosozumab represent different ways of interfering
with bone remodeling. Both lead to uncoupling of bone
resorption and bone formation. Normal bone remodeling
consists of bone resorption followed by bone formation. The
remodeling balance describes the difference between resorp-
tion depth and thickness of the new wall formed [17]. The
balance can be positive (usual in younger individuals) or
negative (in postmenopausal women and elderly men). None
of the existing treatments are capable of uncoupling bone
remodeling. The antiresorptive treatments; bisphosphonates
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whereas the anabolic treatment; teriparatide stimulates both
formation and resorption.
Odanacatib suppresses bone resorption consistently. Bone
formation is also initially suppressed; however, the suppres-
sion is relieved after 1e2 years of treatment, creating a state of
uncoupling of bone resorption and bone formation [56,66].
The fracture outcome of the LOFT trial seems to be similar to
what can be obtained with the currently available anti-
resorptives [74]. It therefore remains to be shown if the
uncoupling of bone resorption and formation has any clinical
relevant consequences.
Romosozumab and blosozumab strongly stimulate bone
formation during the first 6 months of treatment [132,137]. At
the same time bone resorption is suppressed for the first
2 months, returns to baseline levels and then decreases below
baseline levels for the remaining of the treatment period. It
seems as if bone resorption and formation is uncoupled for at
least the first 6 months. Changes in BMD are impressive,
however, if these changes translate into an anti-fracture effi-
cacy superior to what can be achieved with the current anti-
resorptive and anabolic treatments remains to be seen.
The ultimate goal for the treatment of osteoporosis is
avoiding fractures. It is currently being considered if
measurable targets can be identified for osteoporosis treatment
[149]. If such a target can be defined, it raises at least two new
questions. First of all, how should this target be reached? For
many patients this would need repeated courses of anabolic
therapy. Secondly, how the target should be maintained once it
has been reached?
A potent anabolic treatment; teriparatide is already
available and has been demonstrated to be superior to anti-
resorptives in increasing BMD and preventing vertebral
fractures [150], however, teriparatide can only be used once
in the individual patient and severely affected patients
clearly needs more than one anabolic treatment period to
remain free of fractures for the rest of their lives. The
repeated use of romosozumab has been investigated in the
phase 2 study, however, the results have not been published
yet, however, sequential use of romosozumab and an anti-
resorptive may be a possible scenario for the most severely
affected patients. In less severely affected patients a potent
antiresorptive may be sufficient to reach the target. For both
groups of patients the question of how to maintain the target,
once it is reached, remains to be answered. No clinical
studies have addressed this question. However, it is clear
from the studies investigating stopping treatments that this
leads to rapid bone loss with all treatments except
bisphosphonates. Bisphosphonate treated patients may be
able to have a shorter or longer treatment break, however,
patients treated with all other treatments should either stay
on these treatments or be transitioned to another treatment
capable of maintaining the target with limited risk of side
effects. If odanacatib and romosozumab, the two new treat-
ments currently investigated in phase 3 clinical studies,
demonstrate anti-fracture efficacy at least at the same level
as the best of the currently approved treatments and getapproved, they will become valuable tools for improving the
treatment of osteoporosis.
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